Cargando…

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

BACKGROUND: BCOR (BCL6 corepressor) is an epigenetic regulator gene involved in the specification of cell differentiation and body structure development. Recurrent somatic BCOR mutations have been identified in myelodysplastic syndrome (MDS). However, the clinical impact of BCOR mutations on MDS pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiao, Xu, Feng, Zhang, Zheng, Guo, Juan, He, Qi, Song, Lu-Xi, Wu, Dong, Zhou, Li-Yu, Su, Ji-Ying, Xiao, Chao, Chang, Chun-Kang, Wu, Ling-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404357/ https://www.ncbi.nlm.nih.gov/pubmed/34461985 http://dx.doi.org/10.1186/s13148-021-01157-8

Ejemplares similares

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
por: Davies, Helen R., et al.
Publicado: (2019)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
por: Liu, Xiaozhen, et al.
Publicado: (2023)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

BCOR regulates mesenchymal stem cell function by epigenetic mechanisms
por: Fan, Zhipeng, et al.
Publicado: (2009)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
por: Siamoglou, Stavroula, et al.
Publicado: (2023)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes
por: Liu, Liu, et al.
Publicado: (2021)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
por: Wu, De‐hong, et al.
Publicado: (2019)

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma
por: Kang, Jin Hyun, et al.
Publicado: (2021)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
por: Zhao, Guangjie, et al.
Publicado: (2021)

ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling
por: Zhao, Guangjie, et al.
Publicado: (2022)

Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
por: Lee, Paul, et al.
Publicado: (2022)

BCOR involvement in cancer
por: Astolfi, Annalisa, et al.
Publicado: (2019)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes
por: Saygin, Caner
Publicado: (2023)

Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes
por: Xu, Feng, et al.
Publicado: (2017)

Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies
por: Tanaka, Tomoyuki, et al.
Publicado: (2017)

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes
por: Xu, Feng, et al.
Publicado: (2015)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2016)

Cushing's syndrome secondary to typical pulmonary carcinoid with mutation in BCOR gene: A case report
por: Wu, Yimin, et al.
Publicado: (2017)

Intra‐ and extra‐cranial BCOR‐ITD tumours are separate entities within the BCOR ‐rearranged family
por: Bouchoucha, Yassine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_smipt1se2ac7jbottvb4n7i9ed